Home Healthcare Biotechnology mRNA Synthesis Raw Material Market

mRNA Synthesis Raw Material Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Natural Nucleic Acids, Plasmid DNA, Enzymes), By Application (Vaccine Production, Therapeutics Production, Others), By End Use (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. mRNA Synthesis Raw Material Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Capping Agents
      1. CleanCap Reagents
      2. ARCA (Anti-Reverse Cap Analog)
      3. Others
    2. Nucleotides
      1. Modified Nucleic Acids
        1. N1-methylpseudouridine-triphosphate
        2. 5-Methylcytidine triphosphate (5mCTP)
        3. Others
    3. Natural Nucleic Acids
      1. Adenine
      2. Guanine
      3. Cytosine
      4. Uracil
    4. Plasmid DNA
    5. Enzymes
      1. Polymerase
      2. RNase Inhibitor
      3. DNase
      4. Others
  2. mRNA Synthesis Raw Material Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Vaccine Production
    2. Therapeutics Production
    3. Others
  3. mRNA Synthesis Raw Material Market, By End Use 2022-2034 (USD MILLION/ Units)
    1. Biopharmaceutical & Pharmaceutical Companies
    2. CROs & CMOs
    3. Academic & Research Institutes
  4. Regional mRNA Synthesis Raw Material Market
    1. North America
      1. North America mRNA Synthesis Raw Material Market By Type 2022-2034 (USD MILLION/ Units)
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
      2. North America mRNA Synthesis Raw Material Market By Application 2022-2034 (USD MILLION/ Units)
        1. Vaccine Production
        2. Therapeutics Production
        3. Others
      3. North America mRNA Synthesis Raw Material Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Pharmaceutical Companies
        2. CROs & CMOs
        3. Academic & Research Institutes
      4. U.S.
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      5. Canada
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
    2. Europe
      1. Europe mRNA Synthesis Raw Material Market By Type 2022-2034 (USD MILLION/ Units)
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
      2. Europe mRNA Synthesis Raw Material Market By Application 2022-2034 (USD MILLION/ Units)
        1. Vaccine Production
        2. Therapeutics Production
        3. Others
      3. Europe mRNA Synthesis Raw Material Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Pharmaceutical Companies
        2. CROs & CMOs
        3. Academic & Research Institutes
      4. U.K.
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      5. Germany
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      6. France
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      7. Spain
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      8. Italy
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      9. Russia
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      10. Nordic
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      11. Benelux
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      12. Rest of Europe
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
    3. APAC
      1. APAC mRNA Synthesis Raw Material Market By Type 2022-2034 (USD MILLION/ Units)
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
      2. APAC mRNA Synthesis Raw Material Market By Application 2022-2034 (USD MILLION/ Units)
        1. Vaccine Production
        2. Therapeutics Production
        3. Others
      3. APAC mRNA Synthesis Raw Material Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Pharmaceutical Companies
        2. CROs & CMOs
        3. Academic & Research Institutes
      4. China
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      5. Korea
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      6. Japan
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      7. India
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      8. Australia
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      9. Taiwan
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      10. South East Asia
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      11. Rest of Asia-Pacific
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
    4. Middle East and Africa
      1. Middle East and Africa mRNA Synthesis Raw Material Market By Type 2022-2034 (USD MILLION/ Units)
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
      2. Middle East and Africa mRNA Synthesis Raw Material Market By Application 2022-2034 (USD MILLION/ Units)
        1. Vaccine Production
        2. Therapeutics Production
        3. Others
      3. Middle East and Africa mRNA Synthesis Raw Material Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Pharmaceutical Companies
        2. CROs & CMOs
        3. Academic & Research Institutes
      4. UAE
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      5. Turkey
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      6. Saudi Arabia
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      7. South Africa
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      8. Egypt
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      9. Nigeria
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      10. Rest of MEA
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
    5. LATAM
      1. LATAM mRNA Synthesis Raw Material Market By Type 2022-2034 (USD MILLION/ Units)
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
      2. LATAM mRNA Synthesis Raw Material Market By Application 2022-2034 (USD MILLION/ Units)
        1. Vaccine Production
        2. Therapeutics Production
        3. Others
      3. LATAM mRNA Synthesis Raw Material Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Pharmaceutical Companies
        2. CROs & CMOs
        3. Academic & Research Institutes
      4. Brazil
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      5. Mexico
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      6. Argentina
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      7. Chile
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      8. Colombia
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
      9. Rest of LATAM
        1. Capping Agents
          1. CleanCap Reagents
          2. ARCA (Anti-Reverse Cap Analog)
          3. Others
        2. Nucleotides
          1. Modified Nucleic Acids
            1. N1-methylpseudouridine-triphosphate
            2. 5-Methylcytidine triphosphate (5mCTP)
            3. Others
        3. Natural Nucleic Acids
          1. Adenine
          2. Guanine
          3. Cytosine
          4. Uracil
        4. Plasmid DNA
        5. Enzymes
          1. Polymerase
          2. RNase Inhibitor
          3. DNase
          4. Others
        6. Vaccine Production
        7. Therapeutics Production
        8. Others
        9. Biopharmaceutical & Pharmaceutical Companies
        10. CROs & CMOs
        11. Academic & Research Institutes
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.